Halozyme Therapeutics Q1 2026 Earnings Preview
Source: SeekingAlpha
2026-05-08 17:35:04 ET
More on Halozyme Therapeutics
- Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
- Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
- Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
- GSK licenses Halozyme's Enhanze drug delivery technology
- Halozyme appoints Darren Snellgrove as CFO
Read the full article on Seeking Alpha
For further details see:
Halozyme Therapeutics Q1 2026 Earnings Preview
Halozyme Therapeutics Inc.
NASDAQ: HALO
HALO Trading
-0.62% G/L:
$71.25 Last:
385,134 Volume:
$71.725 Open:
HALO Latest News
May 11, 2026 04:01:00 pm
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
HALO Stock Data
$9,572,395,800
114,186,687
0.24%
276
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
